CPIX - Earnings announcements

NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financial results and provide a company update after the market closes on Tuesday, May 5, 2026. A conference call will be held on May 5 at 4:30 p.m. Eastern Time to discuss the results and update.The link to register is https://register-conf.media-server.com/register/BI31a40566a8cb4846873ec8b25642be3a.Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically c

Cumberland to highlight 2025 financial, international, portfolio and clinical progressNASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million during the fourth quarter of 2025, a 31% increase over the prior year period. Net revenues for the full year 2025 were $44.5 million an 18% increase over the prior year period, achieving the company's target of double digit revenue growth. Cumberland en

NASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026. A conference call will be held on March 3 at 4:30 p.m. Eastern Time to discuss the results and update.The link to register is https://register-conf.media-server.com/register/BI6effc1a9cae9445f9bb0d60817870ffa.Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at

NASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $8.3 million during the third quarter of 2025. Year-to-date revenues for the first nine months of the year totaled $30.8 million, representing an increase of 12% over the first nine months of 2024. Cumberland ended the quarter with approximately $66 million in total assets, $40 million in liabilities and $26 million of shareholders' equity. "We are v

NASHVILLE, Tenn., Oct. 28, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2025 financial results and provide a Company update after the market closes on Tuesday, Nov. 4, 2025. A conference call will be held on Nov. 4 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is: https://register-conf.media-server.com/register/BI93f30c40680943ef8d49bc77222ec17f. Once registered, participants can dial in from their phone using a dial-in and PIN n

NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.8 million during the second quarter of 2025, a 10% increase over the prior year period. Year-to-date revenues for the first six months of the year totaled $22.6 million, representing an increase of 23% over the first half of 2024. Cumberland ended the quarter with approximately $68 million in total assets, $40 million in liabilities and $28 milli

NASHVILLE, Tenn., July 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2025 financial results and provide a Company update after the market closes on Tuesday, August 5, 2025. A conference call will be held on August 5 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is: https://register-conf.media-server.com/register/BI0e0cfee6a381408fa7d3d939d82dfa04. Once registered, participants can dial in from their phone using a dial-in and

NASHVILLE, Tenn., May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. As a result the Company generated a net profit of $1.3 million for the quarter, adjusted earnings of $2.4 million, and cash flow from operations of $3.9 million. Cumberland ended the quarter with approximately $70 million in total assets, $41.6 million in liabil

NASHVILLE, Tenn., April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financial results and provide a Company update after the market closes on Tuesday, May 6, 2025. A conference call will be held on May 6 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is: https://register-conf.media-server.com/register/BIea2bc7f82dd24caea135dbe5460d9b6f. Once registered, participants can dial in from their phone using a dial-in and PIN nu

2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval  NASHVILLE, Tenn., March 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.4 million during the fourth quarter of 2024, an 11.6% increase over the prior year period. Net revenues for the full year 2024 were $38 million. Cumberla

NASHVILLE, Tenn., Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial results and provide a company update after the market closes on Tuesday, March 4, 2025. A conference call will be held on March 4 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIafb49dfab9014db59440ff63e1d827b2. Once registered, participants can dial in from their phone using a dial-in and PIN number

–        New Real World Study of 150,000 Patients Favors Caldolor over ketorolac   – –        DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations   – NASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. The company ended the third quarter of 2024 with $77 million in total assets, $52 million in liabilities and $25 million of shareholders' equity.

NASHVILLE, Tenn., Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024. A conference call will be held on Nov. 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIdd190691b1df432e9f1f65383f53b384. Once registered, participants can dial in from their phone using a dial-in and PIN

NASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024. Highlights include: $9.9 million in net revenue during the second quarter of 2024, an increase of 16% sequentially from the first quarter of 2024.Adjusted earnings of $0.2 million, which represents a $0.8 million improvement over the prior period in 2024.$78.5 million in assets, $52.5 million in liabilities and $26.3 m

NASHVILLE, Tenn., July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024. A conference call will be held on Aug. 6 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIfa6a94515e5548c28e9d77d03c95a13e. Once registered, participants can dial in from their phone using a dial-in and PIN

NASHVILLE, TENN., May 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders' equity. "It has been a steady start to 2024 – and despite some challenges the biopharmaceutical sector is facing in the financial markets amid stubborn inflation and stalled intere

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024. A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIbb2d35bc9570474dabf8b2e3d2e4ca72. Once registered, participants can dial in from their phone using a dial-in and PIN nu

2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn., March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations. Cumberland ended the year with $82 million in total assets – including $18 million in cash, $53 million in liabilities and $30 million of shareholders' equity. "In many ways 2023 was a building year for

NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024. A conference call will be held on March 5 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BI77538b1a0c52414b9e2772846f5498ae.   Once registered, participants can dial in from their phone using a dial-in and PIN num

NASHVILLE, Tenn., Aug. 8, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2023. Highlights include: $10.9 million in revenue during the second quarter, an increase of 6% over the prior year period, and an increase of 18% sequentially from the first quarter of this year.Positive earnings for the second consecutive quarter, with $1.1 million in net income for the first half of the year.Adjusted earn

NASHVILLE, Tenn., Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023. A conference call will be held on Aug. 8 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIeb03c2e461914b7d94f99de2f7535170.    Once registered, participants can dial in from their phone using a dial-in and P

NASHVILLE, Tenn., May 9, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that the Company's product portfolio of FDA-approved brands delivered combined revenues of $9.2 million during the first quarter of 2023. Net income for the period was $0.2 million, or $0.01 a share, resulting in adjusted earnings of $1.7 million, or $0.11 a share. The Company ended the first quarter with $89 million in total assets, $53 million in total liabilities, and $36 million of shareholders' equity. Cumberland will report its

NASHVILLE, Tenn., May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023. A conference call will be held on May 9 at 4:30 p.m. Eastern Time, to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BI723fac45344448bbb1833dbb8fa667f3. Once registered, participants can dial in from their phone using a dial-in and PIN num

2022 highlights include its acquisition of Sancuso® and move to new headquarters NASHVILLE, Tenn., March 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company today announced full year 2022 financial results and provided a Company update. Net revenues grew 17% over the prior year to $42 million, resulting in $8 million in cash flow from operations. As of December 31, 2022, the Company's total assets were $93 million, including $20 million in cash. Total liabilities were $57 million and total shareholders' equity was $36 milli

NASHVILLE, Tenn., Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023. A conference call will be held March 7 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIc9d03deed82d47389284c0538fb62962. Once registered, participants can dial in from their phone using a dial-in and PIN number t

Company Also Delivers Growing Cash Flow from Operations NASHVILLE, Tenn., Nov. 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $11.4 million during the third quarter of 2022 - a 41% increase over the prior year period. Cumberland also reported a 19% increase in net revenues for the first nine months of the year compared to the same period in 2021. The Company ended the third quarter with $91 million in total assets, $53 mil

NASHVILLE, Tenn., Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financial results and provide a company update after the market closes on Tuesday, Nov. 8, 2022. A conference call will be held Nov. 8 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BI21ae99e384c446cfb00fbab05f8bf1a3. Once registered, participants can dial in from their phone using a dial-in and PIN numbe

Expanding portfolio of FDA approved brands driving double digit growth NASHVILLE, Tenn., Aug. 9, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $10.3 million during the second quarter of 2022 – a 14% increase over the prior year period. Cumberland also reports a 10% increase in net revenues for the first half of the year compared to the same period in 2021. Year-to-date cash flow from operations were $2.2 million. The Company

NASHVILLE, Tenn., Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022. A conference call will be held Aug. 9 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at https://register.vevent.com/register/BIcc5e9791aa7343d9927dca16dc4cf493. Once registered, participants can dial in from their phone using a dial-in and PIN numb

The Nashville-based specialty pharmaceutical company issues first quarter 2022 financial results and a company update NASHVILLE, Tenn., May 10, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company today announced that the Company's product portfolio of FDA-approved brands delivered combined revenues of $11.2 million during the first quarter of 2022, - which is a 6% increase over the prior year period.  Adjusted earnings for the quarter were $0.5 million, or $0.03 a share.  The company ended the first quarter with $96.7 million in total assets, $55.9 million in total liabilities, and $41.0 million of shareholders' equity. Cumberland will repo

NASHVILLE, Tenn., May 3, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2022 financial results and provide a company update after the market closes on Tuesday, May 10, 2022. A conference call and live internet webcast will be held on May 10 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial (877) 303-1298 (for U.S. callers) or (253) 237-1032 (for international callers). A rebroadcast of the teleconference will be available for

NASHVILLE, Tenn., March 8, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company today announced full year 2021 financial results and provided a company update. Net revenues totaled $36 million, resulting in $6 million in cash flow from operations. As of December 31, 2021, the company's total assets were $84 million, including $27 million in cash. Total liabilities were $42 million, including $15 million on its credit facility and total shareholders' equity was $43 million. "Despite the continued challenges of operating during a

NASHVILLE, Tenn., March 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceuticals company, announced today that it will release annual 2021 financial results and provide a company update after the market closes on Tuesday, March 8, 2022. A conference call and live internet webcast will be held on March 8 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial (877) 303-1298 (for U.S. callers) or (253) 237-1032 (for international callers). A rebroadcast of the teleconference will be available for one wee

NASHVILLE, Tenn., Nov. 2, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release third quarter 2021 financial results and provide a Company update after the market closes on Tuesday, November 9, 2021. A conference call and live internet webcast will be held on November 9 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dial

NASHVILLE, Tenn., Aug. 10, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today is providing a company update and second quarter 2021 financial results. Net revenues from continuing operations during the quarter were $9.1 million and totaled $19.6 million for the first half of 2021. The company also recorded an additional $500,000 in revenue during the second quarter and $1 million year to date, associated with divested product rights for two brands it is no longer distributing. While there was a slight decline in revenu

NASHVILLE, Tenn., Aug. 3, 2021 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced today that it will release second quarter 2021 financial results and provide a Company update after the market closes on Tuesday, August 10, 2021. A conference call and live internet webcast will be held on Tuesday, August 10, 2021, at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be ac